{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:16:18Z","timestamp":1790766978589,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T00:00:00Z","timestamp":1553126400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"crossref","award":["EXC 1003"],"award-info":[{"award-number":["EXC 1003"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"crossref","award":["None"],"award-info":[{"award-number":["None"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","award":["None"],"award-info":[{"award-number":["None"]}],"id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s00277-019-03651-9","type":"journal-article","created":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T13:02:51Z","timestamp":1553259771000},"page":"1393-1401","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Phase II clinical trial of pazopanib in patients with acute myeloid leukemia (AML), relapsed or refractory or at initial diagnosis without an intensive treatment option (PazoAML)"],"prefix":"10.1007","volume":"98","author":[{"given":"Torsten","family":"Kessler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Koschmieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Schliemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Crysandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Henrik","family":"Mikesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"von Stillfried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Stelljes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Pohlen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Vehring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Wardelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eike","family":"Bormann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Gerss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim H.","family":"Br\u00fcmmendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"M\u00fcller-Tidow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3030-6567","authenticated-orcid":false,"given":"Wolfgang E.","family":"Berdel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,21]]},"reference":[{"key":"3651_CR1","doi-asserted-by":"publisher","DOI":"10.3410\/M2-55","volume":"2","author":"O Abdel-Wahab","year":"2010","unstructured":"Abdel-Wahab O, Levine RL (2010) Recent advances in the treatment of acute myeloid leukemia. F1000 Med Rep 2:55. \n                    https:\/\/doi.org\/10.3410\/M2-55","journal-title":"F1000 Med Rep"},{"issue":"1","key":"3651_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1200\/JCO.2007.15.4245","volume":"27","author":"T Buchner","year":"2009","unstructured":"Buchner T, Berdel WE, Haferlach C, Haferlach T, Schnittger S, Muller-Tidow C, Braess J, Spiekermann K, Kienast J, Staib P, Gruneisen A, Kern W, Reichle A, Maschmeyer G, Aul C, Lengfelder E, Sauerland MC, Heinecke A, Wormann B, Hiddemann W (2009) Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol 27(1):61\u201369. \n                    https:\/\/doi.org\/10.1200\/JCO.2007.15.4245","journal-title":"J Clin Oncol"},{"issue":"26","key":"3651_CR3","doi-asserted-by":"publisher","first-page":"6567","DOI":"10.1182\/blood-2009-03-208298","volume":"113","author":"S Metzelder","year":"2009","unstructured":"Metzelder S, Wang Y, Wollmer E, Wanzel M, Teichler S, Chaturvedi A, Eilers M, Enghofer E, Neubauer A, Burchert A (2009) Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood 113(26):6567\u20136571. \n                    https:\/\/doi.org\/10.1182\/blood-2009-03-208298","journal-title":"Blood"},{"issue":"5","key":"3651_CR4","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, Dohner K, Marcucci G, Lo-Coco F, Klisovic RB, Wei A, Sierra J, Sanz MA, Brandwein JM, de Witte T, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Krauter J, Schlenk RF, Ganser A, Serve H, Ehninger G, Amadori S, Larson RA, Dohner H (2017) Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med 377(5):454\u2013464. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1614359","journal-title":"N Engl J Med"},{"issue":"11","key":"3651_CR5","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1182\/blood.V78.11.2962.2962","volume":"78","author":"H Ikeda","year":"1991","unstructured":"Ikeda H, Kanakura Y, Tamaki T, Kuriu A, Kitayama H, Ishikawa J, Kanayama Y, Yonezawa T, Tarui S, Griffin JD (1991) Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells. Blood 78(11):2962\u20132968","journal-title":"Blood"},{"issue":"10","key":"3651_CR6","first-page":"699","volume":"3","author":"C Wang","year":"1989","unstructured":"Wang C, Curtis JE, Geissler EN, McCulloch EA, Minden MD (1989) The expression of the proto-oncogene C-kit in the blast cells of acute myeloblastic leukemia. Leukemia 3(10):699\u2013702","journal-title":"Leukemia"},{"issue":"21","key":"3651_CR7","first-page":"7241","volume":"63","author":"R Bieker","year":"2003","unstructured":"Bieker R, Padro T, Kramer J, Steins M, Kessler T, Retzlaff S, Herrera F, Kienast J, Berdel WE, Mesters RM (2003) Overexpression of basic fibroblast growth factor and autocrine stimulation in acute myeloid leukemia. Cancer Res 63(21):7241\u20137246","journal-title":"Cancer Res"},{"issue":"6","key":"3651_CR8","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood.V89.6.1870","volume":"89","author":"W Fiedler","year":"1997","unstructured":"Fiedler W, Graeven U, Ergun S, Verago S, Kilic N, Stockschlader M, Hossfeld DK (1997) Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia. Blood 89(6):1870\u20131875","journal-title":"Blood"},{"issue":"1","key":"3651_CR9","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1182\/blood.V95.1.309","volume":"95","author":"JW Hussong","year":"2000","unstructured":"Hussong JW, Rodgers GM, Shami PJ (2000) Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 95(1):309\u2013313","journal-title":"Blood"},{"issue":"7","key":"3651_CR10","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1038\/sj.leu.2402534","volume":"16","author":"T Padro","year":"2002","unstructured":"Padro T, Bieker R, Ruiz S, Steins M, Retzlaff S, Burger H, Buchner T, Kessler T, Herrera F, Kienast J, Muller-Tidow C, Serve H, Berdel WE, Mesters RM (2002) Overexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemia. Leukemia 16(7):1302\u20131310. \n                    https:\/\/doi.org\/10.1038\/sj.leu.2402534","journal-title":"Leukemia"},{"issue":"8","key":"3651_CR11","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1182\/blood.V95.8.2637","volume":"95","author":"T Padro","year":"2000","unstructured":"Padro T, Ruiz S, Bieker R, Burger H, Steins M, Kienast J, Buchner T, Berdel WE, Mesters RM (2000) Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 95(8):2637\u20132644","journal-title":"Blood"},{"issue":"8","key":"3651_CR12","doi-asserted-by":"publisher","first-page":"2763","DOI":"10.1182\/blood-2002-10-2998","volume":"102","author":"W Fiedler","year":"2003","unstructured":"Fiedler W, Mesters R, Tinnefeld H, Loges S, Staib P, Duhrsen U, Flasshove M, Ottmann OG, Jung W, Cavalli F, Kuse R, Thomalla J, Serve H, O\u2019Farrell AM, Jacobs M, Brega NM, Scigalla P, Hossfeld DK, Berdel WE (2003) A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood 102(8):2763\u20132767. \n                    https:\/\/doi.org\/10.1182\/blood-2002-10-2998","journal-title":"Blood"},{"issue":"3","key":"3651_CR13","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1182\/blood-2004-05-1846","volume":"105","author":"W Fiedler","year":"2005","unstructured":"Fiedler W, Serve H, Dohner H, Schwittay M, Ottmann OG, O\u2019Farrell AM, Bello CL, Allred R, Manning WC, Cherrington JM, Louie SG, Hong W, Brega NM, Massimini G, Scigalla P, Berdel WE, Hossfeld DK (2005) A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 105(3):986\u2013993. \n                    https:\/\/doi.org\/10.1182\/blood-2004-05-1846","journal-title":"Blood"},{"issue":"1","key":"3651_CR14","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1182\/blood.V98.1.241","volume":"98","author":"RM Mesters","year":"2001","unstructured":"Mesters RM, Padro T, Bieker R, Steins M, Kreuter M, Goner M, Kelsey S, Scigalla P, Fiedler W, Buchner T, Berdel WE (2001) Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia. Blood 98(1):241\u2013243","journal-title":"Blood"},{"issue":"15","key":"3651_CR15","first-page":"5465","volume":"9","author":"AM O\u2019Farrell","year":"2003","unstructured":"O\u2019Farrell AM, Foran JM, Fiedler W, Serve H, Paquette RL, Cooper MA, Yuen HA, Louie SG, Kim H, Nicholas S, Heinrich MC, Berdel WE, Bello C, Jacobs M, Scigalla P, Manning WC, Kelsey S, Cherrington JM (2003) An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 9(15):5465\u20135476","journal-title":"Clin Cancer Res"},{"issue":"4","key":"3651_CR16","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1034\/j.1600-0609.2001.0430a.x","volume":"67","author":"B Foss","year":"2001","unstructured":"Foss B, Ulvestad E, Bruserud O (2001) Platelet-derived growth factor (PDGF) in human acute myelogenous leukemia: PDGF receptor expression, endogenous PDGF release and responsiveness to exogenous PDGF isoforms by in vitro cultured acute myelogenous leukemia blasts. Eur J Haematol 67(4):267\u2013278","journal-title":"Eur J Haematol"},{"issue":"12","key":"3651_CR17","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1158\/1535-7163.MCT-06-0323","volume":"5","author":"E Kulimova","year":"2006","unstructured":"Kulimova E, Oelmann E, Bisping G, Kienast J, Mesters RM, Schwable J, Hilberg F, Roth GJ, Munzert G, Stefanic M, Steffen B, Brandts C, Muller-Tidow C, Kolkmeyer A, Buchner T, Serve H, Berdel WE (2006) Growth inhibition and induction of apoptosis in acute myeloid leukemia cells by new indolinone derivatives targeting fibroblast growth factor, platelet-derived growth factor, and vascular endothelial growth factor receptors. Mol Cancer Ther 5(12):3105\u20133112. \n                    https:\/\/doi.org\/10.1158\/1535-7163.MCT-06-0323","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"3651_CR18","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1158\/1535-7163.MCT-07-0193","volume":"6","author":"R Kumar","year":"2007","unstructured":"Kumar R, Knick VB, Rudolph SK, Johnson JH, Crosby RM, Crouthamel MC, Hopper TM, Miller CG, Harrington LE, Onori JA, Mullin RJ, Gilmer TM, Truesdale AT, Epperly AH, Boloor A, Stafford JA, Luttrell DK, Cheung M (2007) Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 6(7):2012\u20132021. \n                    https:\/\/doi.org\/10.1158\/1535-7163.MCT-07-0193","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"3651_CR19","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","volume":"28","author":"CN Sternberg","year":"2010","unstructured":"Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarba JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28(6):1061\u20131068. \n                    https:\/\/doi.org\/10.1200\/JCO.2009.23.9764","journal-title":"J Clin Oncol"},{"issue":"10","key":"3651_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0164499","volume":"11","author":"C Schliemann","year":"2016","unstructured":"Schliemann C, Gerss J, Wiebe S, Mikesch JH, Knoblauch N, Sauer T, Angenendt L, Kewitz T, Urban M, Butterfass-Bahloul T, Edemir S, Vehring K, Muller-Tidow C, Berdel WE, Krug U (2016) A phase I dose escalation study of the triple angiokinase inhibitor nintedanib combined with low-dose cytarabine in elderly patients with acute myeloid leukemia. PLoS One 11(10):e0164499. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0164499","journal-title":"PLoS One"},{"issue":"3","key":"3651_CR21","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","volume":"126","author":"H Dombret","year":"2015","unstructured":"Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC, Candoni A, Recher C, Sandhu I, Bernal del Castillo T, Al-Ali HK, Martinelli G, Falantes J, Noppeney R, Stone RM, Minden MD, McIntyre H, Songer S, Lucy LM, Beach CL, Dohner H (2015) International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood 126(3):291\u2013299. \n                    https:\/\/doi.org\/10.1182\/blood-2015-01-621664","journal-title":"Blood"},{"issue":"21","key":"3651_CR22","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","volume":"30","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, Gau JP, Chou WC, Buckstein R, Cermak J, Kuo CY, Oriol A, Ravandi F, Faderl S, Delaunay J, Lysak D, Minden M, Arthur C (2012) Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 30(21):2670\u20132677. \n                    https:\/\/doi.org\/10.1200\/JCO.2011.38.9429","journal-title":"J Clin Oncol"},{"issue":"24","key":"3651_CR23","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.1182\/blood-2012-04-420596","volume":"120","author":"GJ Ossenkoppele","year":"2012","unstructured":"Ossenkoppele GJ, Stussi G, Maertens J, van Montfort K, Biemond BJ, Breems D, Ferrant A, Graux C, de Greef GE, Halkes CJ, Hoogendoorn M, Hollestein RM, Jongen-Lavrencic M, Levin MD, van de Loosdrecht AA, van Marwijk Kooij M, van Norden Y, Pabst T, Schouten HC, Vellenga E, Verhoef GE, de Weerdt O, Wijermans P, Passweg JR, Lowenberg B (2012) Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK). Blood 120(24):4706\u20134711. \n                    https:\/\/doi.org\/10.1182\/blood-2012-04-420596","journal-title":"Blood"},{"issue":"6","key":"3651_CR24","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/sj.leu.2404632","volume":"21","author":"L Zahiragic","year":"2007","unstructured":"Zahiragic L, Schliemann C, Bieker R, Thoennissen NH, Burow K, Kramer C, Zuhlsdorf M, Berdel WE, Mesters RM (2007) Bevacizumab reduces VEGF expression in patients with relapsed and refractory acute myeloid leukemia without clinical antileukemic activity. Leukemia 21(6):1310\u20131312. \n                    https:\/\/doi.org\/10.1038\/sj.leu.2404632","journal-title":"Leukemia"},{"issue":"1","key":"3651_CR25","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, Frankfurt O, Konopleva M, Wei AH, Kantarjian HM, Xu T, Hong WJ, Chyla B, Potluri J, Pollyea DA, Letai A (2019) Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133(1):7\u201317. \n                    https:\/\/doi.org\/10.1182\/blood-2018-08-868752","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03651-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-019-03651-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03651-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,20]],"date-time":"2020-03-20T00:11:44Z","timestamp":1584663104000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-019-03651-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,21]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["3651"],"URL":"https:\/\/doi.org\/10.1007\/s00277-019-03651-9","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,21]]},"assertion":[{"value":"1 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Institutional review board or independent ethics committee approval and written informed consent from all patients for being included in the study were obtained. The study was performed in accordance with the ethical principles of the Declaration of Helsinki and in compliance with national laws.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Koschmieder declares Consultancy, Honoraria, and Research Funding by Novartis. Dr. Stelljes declares Pfizer Consultancy, Honoraria and Research Funding; MSD Consultancy; JAZZ Honoraria; Amgen Honoraria; Novartis Honoraria. Dr. Lenz reports the following: Celgene Corp. Consultancy, Honoraria, Travel, Accommodations, Expenses, Research Funding and Speakers Bureau; Janssen Consultancy, Honoraria, Travel, Accommodations, Expenses, Research Funding and Speakers Bureau; Roche Consultancy, Honoraria, Travel, Accomodations, Expenses, and Research Funding; Bayer Consultancy, Honoraria, Research Funding and Speakers Bureau; Novartis Research Funding; Gilead Consultancy and Honoraria. Dr. Br\u00fcmmendorf reports Pfizer Consultancy and Research Funding, Novartis Consultancy and Research Funding, Takeda Consultancy, Janssen Consultancy, and Merck Consultancy. Dr. M\u00fcller-Tidow reports Pfizer Research Funding. Dr. Berdel reports research grants by GSK and Novartis. The other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}